Answers are grounded in this paper and cite their sources.
Genome mining reveals secondary metabolites in Fusarium poae, suggesting potential for natural product discovery through metabolomic assessment.
Genome mining of fungal plant pathogens has uncovered biosynthetic gene clusters encoded on lineage-specific accessory chromosomes, revealing untapped potential for novel natural product discovery by metabolomic assessment of fungal populations. In Fusarium poae, a species contributing to Fusarium head blight on cereals, whole-genome sequencing and comparative metabolomics identified an accessory chromosome-associated biosynthetic gene cluster responsible for the production of a novel family of secondary metabolites, the fusadapamides. These linear tripeptides contain l-2,3-diaminopropionic acid (l-Dap), a rare nonproteinogenic amino acid not previously reported in fungi. Biochemical and genetic analyses revealed that F. poae synthesizes l-Dap via an accessory chromosome-encoded two-gene module that uniquely utilizes l-alanine as a substrate, diverging from known bacterial and plant l-Dap biosynthesis pathways. While fusadapamide production appears limited within Fusarium, homologous l-Dap biosynthetic modules were identified across diverse ascomycetes, suggesting a broader role in fungal secondary metabolism. This study highlights the power of using untargeted metabolomics at population-scale to uncover accessory chromosome-linked biosynthetic innovations and expands our understanding of fungal natural product biosynthesis.
No takes yet. Share an insight, caveat, or question.
Witte et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: